Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) news covers the company’s progress as a biopharmaceutical issuer focused on therapies for autoimmune diseases with high unmet medical needs. Investors and followers of AUPH can use this page to review company‑issued updates, financial announcements and clinical data disclosures that shape the outlook for its products and pipeline.
News releases from Aurinia frequently highlight commercial performance and medical data for LUPKYNIS (voclosporin), which the company describes as the first FDA‑approved oral therapy for adult patients with active lupus nephritis. Regular quarterly earnings announcements detail trends in net product sales of LUPKYNIS, license, collaboration and royalty revenue, net income and cash flows. These updates are often accompanied by guidance ranges for total revenue and net product sales, as well as information on the company’s share repurchase plan.
In addition to financial results, Aurinia’s news flow includes clinical and scientific milestones. The company has reported post‑hoc analyses from the AURORA 1 trial, real‑world data from the ENLIGHT‑LN registry and new mechanistic findings on voclosporin, often presented at major rheumatology and nephrology meetings. Separate announcements describe progress with aritinercept (AUR200), a dual BAFF and APRIL inhibitor, including Phase 1 study results and plans for further clinical development in autoimmune diseases.
Visitors to this AUPH news page can review a stream of earnings releases, pipeline updates, medical conference presentations and regulatory‑related communications drawn from company press releases and SEC‑referenced materials. This provides a centralized view of how Aurinia communicates its commercial performance, clinical findings and strategic steps in autoimmune disease drug development.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has scheduled the release of its first quarter 2025 financial and operational results for May 12, 2025, before markets open. The company will host a conference call and webcast at 8:30 AM ET on the same day, where management will review the results and provide a business update. Investors can join via phone by dialing 877-407-9170 (domestic) or +1 201-493-6756 (international). A replay of the webcast will be available on Aurinia's website.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has received a significant endorsement from Institutional Shareholder Services (ISS), a leading independent proxy advisor, for its upcoming 2025 Annual General Meeting scheduled for May 15, 2025.
ISS has recommended shareholders vote "FOR" all Board proposals, including:
- Approval of six director nominees
- Proposed auditor appointment
- Non-binding advisory vote on executive compensation
- Amendment to the Company's Equity Incentive Plan
Shareholders of record as of April 12, 2025, are eligible to vote. All votes must be submitted by 12:00 PM EST on May 13, 2025. Complete voting details and proposals are available in the proxy statement accessible through EDGAR and SEDAR+ platforms.
Concerned shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) have announced their intention to withhold support for CEO Peter Greenleaf at the 2025 Annual Meeting. MKT Capital and Lucien Selce, significant stakeholders since 2019-2020, acknowledge positive changes under new Board Chair Kevin Tang, including:
- Board size reduction from 9 to 6 members
- Appointment of 4 new independent directors
- Discontinuation of non-core R&D programs saving $50M annually
- Launch of $150M share repurchase program
- Elimination of time-based RSUs for performance-based awards
Shareholders criticize Greenleaf's leadership, citing stock price depression at $8 (versus historical highs of $35), lack of transparency regarding patent infringement lawsuits against Hikma, Lotus, and Galenicum, and questionable compensation practices including 1.55M RSUs awarded despite underperformance. They demand Greenleaf's resignation and call for improved transparency, cost optimization, and receptiveness to M&A discussions.
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong financial results for Q4 and full-year 2024. Q4 total revenue reached $59.9M (up 33% YoY), with LUPKYNIS net product sales of $57.6M (up 36% YoY). The company achieved Q4 net income of $1.4M, compared to a loss of $26.9M in Q4 2023.
Full-year 2024 showed total revenue of $235.1M (up 34% YoY) and net product sales of $216.2M (up 36% YoY). The company reported annual net income of $5.8M, improving from a $78M loss in 2023. Cash position stood at $358.5M as of December 31, 2024.
For 2025 guidance, Aurinia expects total revenue of $250-260M and net product sales of $240-250M. The company also initiated a Phase 1 study of AUR200, a dual inhibitor for autoimmune diseases, with initial results expected in Q2 2025.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced that it will release its 2024 fourth quarter and full year financial and operational results on February 27, 2025, before the market opens.
The company's management team will host a conference call and webcast at 8:30 am ET on the same day to review these results and provide a general business update. Interested parties can join the conference call by dialing 877-407-9170 (US) or +1 201-493-6756 (International).
A replay of the webcast will be available on Aurinia's website.
Aurinia Pharmaceuticals (NASDAQ: AUPH) welcomes the American College of Rheumatology's (ACR) 2024 guidelines for lupus nephritis (LN) treatment. The new guidelines recommend LUPKYNIS as first-line therapy in a triple immunosuppressive treatment regimen. Key highlights include steroid tapering to <5 mg/day by six months and achieving proteinuria target of <0.5g/g UPCR by 12 months. The AURORA 1 clinical study showed patients were 81% more likely to achieve complete renal response at 52 weeks with LUPKYNIS combination therapy versus standard treatment. Notably, >80% of patients reached steroid doses of <2.5mg/day by 16 weeks.
Aurinia Pharmaceuticals (NASDAQ: AUPH) presented four posters at ACR 2024, highlighting new data about lupus nephritis (LN) detection and LUPKYNIS® treatment. A key study using the American Rheumatology Network database revealed that 62% of 8,631 SLE patients showed signs suggesting LN, yet many weren't receiving proper kidney screenings. The analysis of Phase 3 AURORA 1 and 2 studies demonstrated significantly higher rates of sustained complete renal response in LUPKYNIS patients compared to placebo. The data emphasizes the need for enhanced LN screening and validates LUPKYNIS's long-term efficacy in treating active LN in adults.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its participation in the upcoming Jefferies Healthcare Conference in London, scheduled for November 19-21, 2024. The company's management team will engage in one-on-one meetings with investors and participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. The session will not be webcasted.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has appointed Craig Johnson to its Board of Directors to support its next phase of growth. Johnson brings over 30 years of experience in senior financial management and governance roles in the biotechnology industry. He has previously served as director at multiple biotech companies including Ardea Biosciences, Adamis Pharmaceuticals, and Mirati Therapeutics, and currently serves as director at Heron Therapeutics. The company also announced the retirement of Dr. Robert T. Foster from the Board.
Aurinia Pharmaceuticals reported strong Q3 2024 results with total net revenue of $67.8 million (24% YoY growth) and net product revenue of $55.5 million (36% YoY growth). The company generated $17.0 million in operating cash flow and maintained $348.7 million in cash and investments. Aurinia announced a strategic restructuring, reducing workforce by 45%, expecting $40 million in annual operating expense savings with a one-time charge of $15-19 million in Q4. The company reaffirmed its 2024 net product revenue guidance of $210-220 million and reported 2,422 patients on LUPKYNIS therapy, representing 25% YoY market penetration growth.
FAQ
What is the current stock price of Aurinia Pharmace (AUPH)?
What is the market cap of Aurinia Pharmace (AUPH)?
